Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ipsen SA announces clinical results of Dysport Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW


Wednesday, 5 Feb 2014 01:00am EST 

Ipsen SA:Announces the results of the international Phase III clinical trial of Dysport Next Generation (DNG) in cervical dystonia and the results of the European Phase II clinical trial of DNG in glabellar lines.Announces its intention to file the first ready-to-use liquid toxin A in Europe and in the Rest of the World.Says DNG was clinically and statistically superior to placebo in the cervical dystonia Phase III study at the dose of 500 units at week 4 after single dose.Says when compared to Dysport, DNG did not demonstrate the statistical non-inferiority in efficacy at week 4.Says DNG showed comparable efficacy to that of Dysport as observed in former Phase III studies.Says DNG was clinically and statistically superior to placebo and comparable to Dysport in the glabellar lines Phase II study at the dose of 50 units after single dose.Says DNG showed safety profiles consistent with the known safety profile of Dysport. 

Related Company News

Company Quote

48.045
0.575 +1.21%
24 Apr 2015